Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

ASRT - Assertio Holdings, Inc. Последние новости | Finranks

Home

ASRT

(ASRT)

NCM – Цена в реальном времени. Валюта: USD

19.39

-0.14 (-0.72%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

19.37

-0.02 (-0.10%)

После закрытия: Mar 27, 2026, 4:14 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?

Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?

Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Wall Street Analysts Predict an 182.79% Upside in Assertio (ASRT): Here's What You Should Know

Wall Street Analysts Predict an 182.79% Upside in Assertio (ASRT): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 182.8% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

Here is how Assertio (ASRT) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates

Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates

Assertio (ASRT) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $3.05. This compares to a loss of $1.65 per share a year ago.

Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript

Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript

Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results

LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today reported financial results for the fourth quarter and full year ended December 31, 2025. Mark Reisenauer, Chief Executive Officer, stated: “Our core asset, Rolvedon, continues to represent a meaningful revenue opportunity, as reflected in both our 20.

Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?

Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?

Here is how Assertio (ASRT) and Aura Biosciences, Inc. (AURA) have performed compared to their sector so far this year.

Видео

No Data

There is no data to display